How do I Apply for a CEP? An Updated Guideline of the EDQM Provides Information
Many companies have already started to submit their authorisation applications electronically. With regard to a centralised marketing authorisation, this has been the only way for some time. For a Certificate of Suitability (CEP) application both ways can still be used, though: sending in paper form or electronic transmission.
The EDQM recently published an updated guidance entitled "Guidance for electronic and paper submissions for certificates of suitability (CEPs) applications". This document describes in detail the use of different formats for the submission and the respective procedure. The following formats are accepted:
•eCTD — This is the format that is used for the electronic submission of authorisation applications. However, the guideline points out that from a technical perspective it remains a 'standalone' dossier, which is distinct from any marketing authorisation eCTD dossier and life cycle. Furthermore, it is recommended to validate the eCTD technically prior to submission to the EDQM (using validation checker tools). If error messages appear during the validation by the EDQM, the submission is blocked or rejected, which delays the whole process of submission. The EDQM recommends the use of this format.
•NeeS — The "non eCTD electronic submission" (NeeS) uses a format different from the CTD. Structure and specification of the format must meet the requirements described in the guidance document of the "EU telematics implementation group for electronic submissions" (TIGes) with the title "TIGes harmonised guidance for non eCTD electronic submissions (NeeS) for human medicinal products in the EU".
•PDF — In this format, the modules 1–3 have to be listed separately. The use of bookmarks is recommended.
To better structure the extensive information additional sections can be introduced in all three formats (extension of granularity). When submitting these documents in paper form, they are initially scanned by the EDQM and then destroyed. Due to this process there can be a delay depending on the volume of the documentation, because the clock-start for the dossier begins only after this process is complete.
Basically, switching from paper to electronic submission is possible and recommended by the EDQM. However, once a company opted for the electronic way, going back to paper dossier is impossible.
The guideline contains 6 Annexes, describing the directory and folder structure of the formats and the granularity levels in more details. Annex 6 is particularly useful as it lists the most common mistakes that may lead to a blocking of the application process.
www.gmp-compliance.org
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...